Table 3 Best responses by evaluable disease in bone/BM compartment and disease location at enrollment in 52 patients treated with naxitamab plus GM-CSF
Patient population | Endpoint | Patients | |
|---|---|---|---|
n (%) | 95% CI, % | ||
Response by evaluable disease in bone/BM compartmenta | |||
Evaluable disease in BM (n = 23) | CR | 17 (74) | 52–90 |
MD | 1 (4) | 0–22 | |
SD | 2 (9) | 1–28 | |
PD | 1 (4) | 0–22 | |
NE | 2 (9) | – | |
Response rate | CR + PR | 17 (74) | 52–90 |
Evaluable disease in bone (n = 50) | CR | 20 (40) | 26–55 |
PR | 9 (18) | 9–31 | |
SD | 13 (26) | 15–40 | |
PD | 6 (12) | 5–24 | |
NE | 2 (4) | – | |
Response rate | CR + PR | 29 (58) | 43–72 |
Response by disease location at enrollment | |||
BM disease only (n = 2) | CR | 1 (50) | 1–99 |
PD | 1 (50) | 1–99 | |
ORR | CR + PR | 1 (50) | 1–99 |
Bone disease only (n = 29) | CR | 10 (35) | 18–54 |
PR | 5 (17) | 6–36 | |
SD | 7 (24) | 10–44 | |
PD | 7 (24) | 10–44 | |
NE | 0 | – | |
ORR | CR + PR | 15 (52) | 33–71 |
Both bone and BM disease (n = 21) | CR | 9 (43) | 22–66 |
PR | 1 (5) | 0–24 | |
MR | 5 (24) | 8–47 | |
SD | 3 (14) | 3–36 | |
NE | 3 (14) | – | |
ORR | CR + PR | 10 (48) | 26–70 |
